Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning
Context Therapeutics' Promising Financial and Preclinical Results Bolster Buy Rating: A Focus on CTIM-76's High Potency and Target Specificity
Promising Potential of CTIM-76 Drug: A Comprehensive Buy Rating Analysis for Context Therapeutics
HC Wainwright & Co. Upgrades Context Therapeutics to Buy, Announces $5 Price Target
Context Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: AstraZeneca (AZN), Context Therapeutics (CNTX)
H.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)
Context Therapeutics' Promising CLDN6 Targeting Asset CTIM-76 and Potential Market Valuation Opportunities: An Analyst's Buy Rating Perspective
Context Therapeutics Analyst Ratings
H.C. Wainwright Downgrades Context Therapeutics (CNTX) to a Hold
Context Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Context Therapeutics, Maintains $4 Price Target
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Context Therapeutics (CNTX)
H.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)
Context Therapeutics (CNTX) Receives a Buy From H.C. Wainwright
H.C. Wainwright Remains a Buy on Context Therapeutics (CNTX)
No Data